Black Diamond Therapeutics, Inc. BDTX
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is an oncology drug developer. Its lead program, Silevertinib (BDTX-1535), is in Phase 2 for EGFR-mutant non-small cell lung cancer; EGFRvIII+ newly diagnosed glioblastoma. Its next catalyst on record is Silevertinib (GBM): Interim PFS analysis of randomized Phase 2 (H1 2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Silevertinib (GBM) — Interim PFS analysis of randomized Phase 2 (H1 2028). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Silevertinib | EGFRm NSCLC (frontline and 2L/3L) | small molecule | Phase 2 |
| Silevertinib | Newly diagnosed EGFRvIII+ glioblastoma (randomized with temozolomide) | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.